Overexpression of eNOS prevents the development of renovascular hypertension in mice

Agata L Gava1, Veronica A Peotta, Antonio M Cabral

  • 1Laboratory of Transgenes and Cardiovascular Control, Physiological Sciences Graduate Program, Health Sciences Center, Federal University of Espirito Santo, Avenida. Marechal Campos 1468, Vitoria, ES 29043-900, Brazil.

Insights

Endothelial nitric oxide synthase (eNOS) gene therapy prevented renovascular hypertension in mice. However, eNOS overexpression did not improve baroreflex sensitivity or alter cardiac autonomic tone in this model.

Area of Science:

  • Cardiovascular Diseases
  • Gene Therapy
  • Hypertension Research

Background:

  • Gene therapy is a valuable tool for investigating cardiovascular diseases.
  • Renovascular hypertension is a significant cardiovascular condition.
  • Endothelial nitric oxide synthase (eNOS) plays a role in vascular function.

Purpose of the Study:

  • To investigate the therapeutic potential of endothelial nitric oxide synthase (eNOS) overexpression in a mouse model of renovascular hypertension.
  • To assess the impact of eNOS gene therapy on arterial pressure, baroreflex sensitivity, and autonomic tone in renovascular hypertension.

Main Methods:

  • C57BL/6 mice underwent either a two-kidney one-clip (2K1C) surgery or sham operation.
  • Mice received intravenous injections of adenovirus carrying either the eNOS gene or a beta-galactosidase (beta-gal) reporter gene.
  • Arterial pressure, baroreflex sensitivity, and cardiac sympathetic/parasympathetic tone were measured 14 days post-injection.

Main Results:

  • 2K1C mice with beta-gal showed significantly elevated mean arterial pressure compared to sham controls (121 vs. 96 mm Hg).
  • eNOS overexpression prevented the rise in arterial pressure in 2K1C mice (100 vs. 99 mm Hg).
  • Baroreflex sensitivity was reduced in 2K1C-beta-gal mice but not improved by eNOS overexpression. Cardiac sympathetic tone was augmented and vagal tone reduced in 2K1C mice, irrespective of eNOS therapy.

Conclusions:

  • Overexpression of eNOS effectively prevents the development of 2K1C renovascular hypertension in mice.
  • eNOS gene therapy did not ameliorate the impaired baroreflex sensitivity or altered cardiac autonomic function observed in this hypertension model.
  • These findings highlight the specific role of eNOS in regulating blood pressure in renovascular hypertension but suggest limitations in addressing broader cardiovascular autonomic dysregulation.

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...